Merck Showcases Oncology Pipeline Results at ESMO 2026
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
10:47:30 AM UTC
SquawkNews
Merck said three pivotal Phase 3 trial results, including first-time data for intismeran and sacituzumab tirumotecan, will be presented in late-breaking Presidential Symposia at ESMO 2026. The company will also host an Oncology Investor Event on Oct. 26.Material DetailsContext by AI AnalystThis is…